Prescribing information

 

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate.

Individual patient dosing may vary - please consult the Prescribing Information for full details.

Introducing the new 300 mg autoinjector pen: All the benefits of the Complete Cosentyx Approach™* in adult plaque psoriasis in ONE UnoReady® pen1–3

Image. UNOREADY® 300mg PEN key benefits. One monthly maintenance injection.¹ Overall , 100% of patients found the UNOREADY® 300mg PEN easy to use² Less than 1% injection site reactions at one year³

UNOREADY® 300 mg PEN key features and benefits.

 

UnoReady® 300 mg pen:
Similar administration steps as the SensoReady® 150 mg pen, with a few differences.1,4,5

 

UNOREADY® 300 mg PEN administration steps
SENSOREADY® 150 mg PEN administration steps
 
Teaser banner. Watch an injection demonstration.
Teaser banner. Find out more about Cosentyx® dosing and administration
 

The UnoReady® 300 mg pen will be available via the homecare channels and your pharmacy.
If you would like to order a demo-kit or for further information on the UnoReady® 300 mg pen, please contact us here

 

Convenient dosing schedule that delivers all the benefits of Cosentyx 

Image. Look better, move better, feel better.

Image. Look better, move better, feel better.

Image. Look better, move better, feel better.

 

*The Complete Cosentyx Approach™ is defined as efficacy in both skin and persistent nail and scalp PsO, as well as psoriatic arthritis, and improvements in quality of life.
†Individual patient dosing may vary - please consult the Prescribing Information for full details.
N=37, moderate-to-severe plaque psoriasis patients at Week 28.2
§In a clinical study, adverse events with the preferred term injection-site bruising or injection-site pain due to administration of Cosentyx using the UnoReady® pen over 52 weeks.

 

DMARD, disease-modifying anti-rheumatic drugs; MTX, methotrexate; TNF, tumour necrosis factor.

 

References

  1. Cosentyx Summary of Product Characteristics.
  2. Novartis data on file. CAIN457A2325 Data Analysis Report. Satisfaction with self-injection. December 2020.
  3. Novartis data on file. CAIN457A2325 Data Analysis Report. Injection site reaction rate. December 2020.
  4. Cosentyx EPAR Product Information. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx [Accessed November 2021].
  5. Paul C, et al. J Eur Acad Dermatol Venereol 2015;29(6):1082–1090.
Rate this content: 
No votes yet
UK | February 2022 | 187468
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]